Cowen Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 7:14 AM EDTWedbush initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating and a price target of $20.
"BOLDs AAV-based gene therapy programs are targeted to address significant unmet medical need in life-threatening rare diseases. With clinical readouts expected in 2017 from three wholly-owned... More
